BFG
DSGN icon

Bleakley Financial Group’s Design Therapeutics DSGN Stock Holding History

Bleakley Financial Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,266
Closed -$81.9K – 637
2024
Q4 		$81.9K Buy
13,266
+1,675
+14% +$9.7K ﹤0.01% 999
2024
Q3 		$62.4K Sell
11,591
-41
-0.4% -$193 ﹤0.01% 992
2024
Q2 		$39K Buy
11,632
+137
+1% +$534 ﹤0.01% 991
2024
Q1 		$46.3K Buy
+11,495
New +$30.7K ﹤0.01% 971

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bleakley Financial Group's DSGN Position: Q1 2025 in Review

Bleakley Financial Group sold out of Design Therapeutics (DSGN) in Q1 2025, closing a stake of 13,266 shares — an estimated $81.9K sold.

Bleakley Financial Group first reported a position in DSGN in Q1 2024 and held it in 4 quarters. The position peaked at $81.9K in Q4 2024. 98 funds tracked by Wall St. Rank hold DSGN as of Q1 2025.

  • Bleakley Financial Group reported no remaining Design Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 13,266 Design Therapeutics shares in Q1 2025, an estimated $81.9K.
  • Bleakley Financial Group first reported a position in Design Therapeutics in Q1 2024 and held it in 4 quarters.
  • Bleakley Financial Group's Design Therapeutics position peaked at $81.9K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.